US FDA approves Bristol Myers' blood cancer treatment
13/08/2026 21:15
US FDA approves Bristol Myers' blood cancer treatment Aug 13 (Reuters) - The U.S. FDA on Thursday approved Bristol Myers Squibb's BMY.N combination treatment for patients with a rare form of blood cancer whose illness had relapsed or not responded to other treatments, the health regulator said.
(Reporting by Siddhi Mahatole and Sneha S K in Bengaluru; Editing by Shreya Biswas)
Recent news on Johnson & Johnson
See all newsEli Lilly hits record high as healthcare stocks rally
Kenvue loses bid for rehearing after Tylenol autism lawsuits revived (updated)
Brief: Johnson & Johnson Announces New Data For Tremfya
Kenvue loses bid for rehearing after Tylenol autism lawsuits revived
Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin